Headlands Research
Runs clinical trial sites and recruitment
Physician – Clinical Trials - MD/DO
About the job
- Previous experience as a Principal Investigator or Sub-Investigator for clinical research trials.
- Active and unencumbered license to practice as a Medical Doctor or Doctor of Osteopathy within the state of Arkansas.
- Must be board-certified or board-eligible.
- Excellent communication and leadership skills, with the ability to collaborate effectively with sponsors, research teams, and external stakeholders.
- Familiarity with regulatory requirements, Good Clinical Practice guidelines, and industry best practices in clinical research.
- Strong organizational skills and attention to detail, with the ability to manage multiple projects simultaneously in a fast-paced environment.
- Headlands Research will never ask a candidate for personal identifiable information (date of birth, social security number, driver’s license information, etc) via email or messenger tools, or for a financial deposit of any kind.
- Headlands Research is an Equal Opportunity Employer. We do not discriminate on the basis of race, color, religion, age, sex, national origin, disability status, genetic information, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state, or local laws.
- Lead and oversee clinical trials conducted at Headlands Research sites, ensuring compliance with protocol requirements, regulatory standards, and ethical guidelines.
- Provide leadership and mentorship to site staff, fostering a culture of inclusivity, diversity, and professionalism within the research team.
- Participate in investigator meetings and educational initiatives to stay updated on advancements in clinical research and diversity initiatives.
- Obtain IRB approval for study initiation and any protocol modifications.
- Oversee subject safety, trial conduct compliance, and the informed consent process.
- Communicate effectively with stakeholders including sponsors, monitors, regulators, and research network leadership.
- Provide ongoing training and support to research staff.
About the company
Headlands Research runs a network of clinical trial sites across North America to support the development of new medicines. It provides research services to pharmaceutical and biotech companies by running and managing clinical trials, with a strong focus on recruiting and keeping diverse patient populations involved. What it does is coordinate and conduct trials at its sites, manage study logistics, and collect data so sponsors can evaluate safety and efficacy of therapies. Its differentiators include a large multinational network of sites, a dedicated emphasis on diverse and inclusive recruitment, and end-to-end trial management from site operations to data collection. The goal is to accelerate the development of new medical therapies by delivering high-quality, efficient, and inclusive clinical trials for sponsors.
Company Size
201-500
Company Stage
Acquired
Total Funding
$23.4M
Headquarters
Lake Worth, Texas
Founded
2018
Get referred to Headlands Research
See people who can refer or advise you
Simplify's Take
What believers are saying
- Grand Rapids opened September 10, 2026, adding rheumatology, autoimmune, and cardiometabolic capacity.
- Bellingham launched August 5, 2026, reaching 615,000 people for CNS enrollment.
- Headlands named Brandon Pallott CCO on September 8, 2026, sharpening commercial execution after THL ownership.
What critics are saying
- Rapid openings in Bellingham, Sacramento, Lincoln, and Grand Rapids strain quality control through 2027.
- Big CROs and site networks like IQVIA and Labcorp intensify sponsor competition for the same trials.
- Past Houston and Lake Charles closures showed staffing shortages can force site shutdowns and study transfers.
What makes Headlands Research unique
- Headlands has completed 5,000-plus trials across North America and Europe by September 2026.
- THL’s 2025 acquisition funds centralized infrastructure, technology, and faster sponsor startup.
- Investigator-led sites in rheumatology, CNS, and cardiometabolic care deepen protocol execution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Unlimited Paid Time Off
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -2%2 year growth
↓ -2%Headlands Research announces new de novo clinical research site in Grand Rapids, michigan. Science · SEP 10, 2026 PR Newswire The new site, expected to open later this year, will expand rheumatology, autoimmune disease, and cardiometabolic trial capacity in the Midwest WEST PALM B... The new site, expected to open later this year, will expand rheumatology, autoimmune disease, and cardiometabolic trial capacity in the Midwest WEST PALM BEACH, Fla. and GRAND RAPIDS, Mich., Sept. 10, 2026 /PRNewswire/ - Headlands Research, a leading clinical trial site network, today announced the establishment of Headlands Research - Grand Rapids, a new de novo clinical research site led by board-certified rheumatologist and internist Eric Slavin, MD, FACP, FACR. The site is currently being developed and is expected to open later this year. "Headlands Research is committed to being the partner of choice for sponsors and CROs, giving them access to experienced investigators, engaged patient populations, and strong therapeutic knowledge," said Kyle Burtnett, CEO of Headlands Research. "Dr. Slavin brings exceptional clinical expertise and a deep commitment to his patients. Rheumatology and autoimmune disease are therapeutic areas where sponsor demand continues to climb, and Grand Rapids gives us both a proven investigator and a strong new site to meet it." Headlands Research - Grand Rapids will expand Headlands Research's presence in the Midwest and strengthen the organization's capabilities in rheumatology, bone and joint conditions, autoimmune and inflammatory diseases, and related therapeutic areas. The site will also conduct studies across general medicine, cardiometabolic disease, chronic kidney disease, obesity, hypertension, hyperlipidemia, and vaccines. Dr. Slavin has participated in multiple Phase III and IV clinical trials evaluating novel therapies for rheumatoid arthritis and other autoimmune conditions, including biologic and targeted disease-modifying treatments, with research experience spanning sponsor-funded multicenter studies and biosimilar development. A Fellow of the American College of Rheumatology, Dr. Slavin has been consistently recognized for excellence in patient care, earning Grand Rapids Magazine Top Doctor recognition from 2021 through 2026. "I'm excited to join Headlands and bring our research capabilities to participants and families throughout the Grand Rapids community," said Dr. Slavin. "Our team is committed to conducting high-quality research and providing participants with the same level of care, attention, and respect that they expect from their clinical providers." The opening of Headlands Research - Grand Rapids builds on the site organization's continued growth across key U.S. markets. In recent months, Headlands has strengthened its network through the acquisition of two CTR sites, now operating as Headlands Research - Sacramento and Headlands Research - CTR-Lincoln, as well as the opening of Headlands Research - Western Washington. Together, these additions expand Headlands Research's therapeutic capabilities across new U.S. markets. About Headlands Research Headlands Research is a leading clinical trial site network with a mission to improve lives by advancing innovative medical therapies. Its group of exceptional sites focuses on large-volume recruitment of diverse and specialty participant populations while delivering the highest quality data. Headlands Research's principal investigators are proven industry leaders in their fields with expertise in a wide variety of indications. Utilizing expert recruitment strategies and access to diverse participants through its site databases and physician partnerships, Headlands Research has successfully completed more than 5,000 clinical trials. Additional information about the company is available at www.headlandsresearch.com. SOURCE Headlands Research Published by News Desk · WeeklyReviewer The WeeklyReviewer news desk monitors breaking developments around the clock - sourcing, verifying, and publishing real-time industry news across business, technology, politics, science, sports, and world affairs. Every story that comes through the Live Wire is reviewed for accuracy before publication, keeping our readers ahead of the curve without the noise.
Landmark Funeral Group names Jackie Short chief operating officer. Landmark Funeral Group has announced the appointment of Jackie Short as chief operating officer. Short joins Landmark from Headlands Research, where she served as chief operating officer of the private equity-backed clinical research network operating across the United States and Canada. Throughout her career, she has led multi-site organizations through rapid growth, integration and operational transformation, building the leadership teams, operating models and infrastructure that enable local teams to deliver exceptional care while adapting to change. Short's appointment reflects Landmark's continued investment in the leadership and operational excellence that support its growing network of locally owned and operated funeral homes. As the company expands, Landmark is strengthening the systems and local leadership that allow each funeral home to preserve its legacy while continuing to serve families in the community. "As Landmark continues to grow, we're building an organization that gives our partner funeral homes the leadership, support and resources they need to succeed," said Seb D'Appolonia, president and CEO of Landmark Funeral Group. "Jackie has spent her career leading complex, multi-site organizations while developing strong teams and a culture of operational excellence. Her experience, leadership style and commitment to people make her an outstanding addition to Landmark as we continue investing in the long-term success of our funeral homes." As COO, Short will oversee Landmark's operations across its partner firms, with a focus on developing local leadership, establishing scalable operating models, and strengthening the cultural foundation that connects the network. Her focus will be on giving funeral directors and their teams the resources and operational structure to best serve families, while preserving the autonomy and identity that make each funeral home unique. In addition to her most recent role as COO of Headlands Research, Short's career spans some of health care's most operationally demanding environments. Previously, as vice president of central operations at Marathon Health, she guided the merger of Marathon Health and Its Health through the height of the COVID-19 pandemic. She also held regional and division leadership roles at DaVita Kidney Care and Trilogy Health Services, where she specialized in strengthening operations, developing leaders and building scalable operating models across multi-site organizations. "The most important lesson I've learned is that organizations succeed when the people closest to the families they serve are trusted, supported and empowered," said Short. " That's what drew me to Landmark. The company is committed to strengthening community funeral homes while preserving the values and local relationships that make each one unique. I'm excited to help build the operational foundation that allows our funeral professionals to focus on what matters most: serving families." About Landmark Funeral Group Landmark works alongside dedicated funeral professionals who share a commitment to compassionate care, operational excellence and preserving the legacy of community funeral homes. With advanced technology integrations, strategic resources, and thoughtful investment, Landmark helps independent funeral homes grow and thrive while enabling local teams to continue serving families with the care and trust that define the profession. Learn more at www.landmarkfuneralgroup.com. Leave a message. Your email address will not be published. Required fields are marked *
Headlands Research has opened a new clinical research site in Bellingham, Washington, led by board-certified psychiatrist Dr Matthew Bogoyas. The facility targets central nervous system research in an underserved market covering more than 615,000 people within a 50-mile radius. Dr Bogoyas, recently elected Fellow of the American Psychiatric Association, brings experience in Phase 2 and Phase 3 studies across major depressive disorder, treatment-resistant depression, and PTSD. Local physicians recorded over 1,200 diagnosis claims for depression, bipolar disorder, anxiety, and insomnia in 2025. The opening follows Headlands Research's recent acquisition of Clinical Trials Research, which added sites in Sacramento and Lincoln, California. The company has completed more than 5,000 clinical trials.
Headlands Research expands pacific northwest presence with new clinical research site in bellingham, washington. August 5, 2026 WOBN news, syndication comments off on Headlands Research expands pacific northwest presence with new clinical research site in bellingham, washington. Led by a board-certified psychiatrist and 2025 APA Fellow, the site gives sponsors access to more than 615,000 participants in an untapped CNS research market WEST PALM BEACH, Fla. and BELLINGHAM, Wash., Aug. 5, 2026 /PRNewswire/ - Headlands Research, a leading clinical trial site...
Headlands Research acquires CTR, expands California. Overview of the acquisition. Headlands Research, a leading clinical trial site network, has acquired Clinical Trials Research (CTR) - a privately owned clinical research organization based in Sacramento and Lincoln, California. The announcement came on June 30, 2026, marking a significant step in Headlands' strategy to deepen its California presence. Following the acquisition, CTR's two locations will rebrand as Headlands Research - Sacramento and Headlands Research - CTR Lincoln. Together, they add two fully operational research sites to Headlands' growing North American and European network. Why this deal matters for clinical research. Clinical trial site consolidation is accelerating across the U.S. Yet not all acquisitions bring equal value. This one does. CTR offers something rare: two well-established sites, a 25-year operational history, and an investigator team that pharmaceutical sponsors already know and trust. Kyle Burtnett, Chief Executive Officer of Headlands Research, explained the rationale clearly. "By pairing that depth with Headlands' infrastructure, we advance our objective of being the partner of choice for pharmaceutical companies and CROs by providing additional capabilities and scale to our cardiometabolic therapeutic area," he said. Furthermore, the acquisition accelerates Headlands' ability to offer sponsors faster study startup, stronger patient recruitment, and reliable data quality - all at scale. CTR's 25-year track record. Therapeutic areas of expertise. CTR brings deep clinical expertise across a range of cardiometabolic and metabolic indications. Specifically, the sites have run trials across the following conditions: * High cholesterol and hypertension * Heart failure prevention * Obesity and overweight management * Type 2 diabetes and diabetic peripheral neuropathic pain * Fatty liver disease (NAFLD/NASH) * Chronic idiopathic constipation This breadth of indications strengthens Headlands' existing cardiometabolic portfolio. Moreover, it positions the network to pursue more complex, multi-indication studies for both sponsors and CROs. Key clinical trial metrics. These numbers reflect a site that performs. Rapid study startup and high-quality data retention are core strengths that sponsors value most - and CTR consistently delivers both. Meet the leadership: Dr. Jeffrey D. Wayne. Dr. Jeffrey D. Wayne, MD, leads CTR's clinical operations. He has served as a principal investigator since 1992, building one of California's most respected community-based research practices over more than three decades. Dr. Wayne holds his medical degree from the University of Southern California Keck School of Medicine. He also serves as clinical faculty at the University of California, Davis School of Medicine. His research spans cardiovascular disease, diabetes, respiratory conditions, and both women's and men's health. His perspective on the acquisition reflects a practitioner-first mindset. "Clinical research has been my career passion, and our team has built a trusted research practice," Dr. Wayne noted. "Joining Headlands Research gives us the infrastructure and network to bring more patients into research, expand the therapeutic areas that we can offer our community, and maintain the quality our sponsors rely on." Notably, Dr. Wayne's long tenure and board certification in internal medicine give CTR - and now Headlands - strong investigator credibility with regulatory bodies and sponsors alike. Strategic impact on Headlands Research. Strengthening the cardiometabolic portfolio. Headlands already conducts trials across CNS, vaccines, metabolic diseases, obesity, and respiratory disease. However, cardiometabolic disorders represent one of the highest-demand therapeutic areas for sponsor investment globally. As a result, adding CTR's concentrated cardiometabolic expertise directly enhances Headlands' competitive positioning. Additionally, the Sacramento market offers access to a large and diverse patient population - a key driver for trial enrollment success in chronic disease studies. Network growth across North America. This acquisition follows a broader pattern of strategic growth. Earlier in 2025, Headlands opened a Twin Cities clinical research site to extend its Upper Midwest reach. The company also entered the Caribbean with the acquisition of CMRCenter. California, therefore, represents another deliberate geographic move - not an opportunistic one. Each site Headlands acquires strengthens the overall network's ability to deliver enrollment scale, therapeutic depth, and operational consistency to pharmaceutical partners. What this means for sponsors and CROs. For pharmaceutical companies and contract research organizations, this acquisition delivers three immediate benefits: Faster Study Startup - CTR's teams have refined startup processes across 300+ trials. Sponsors gain access to a site that reduces the time between contract execution and first patient enrolled. Stronger Enrollment Capabilities - The Sacramento and Lincoln sites serve a large, diverse Northern California patient base. This expands enrollment potential for cardiometabolic, metabolic, and chronic disease protocols. Proven Investigator Relationships - Dr. Wayne's three decades of principal investigator experience translate directly into sponsor confidence. Experienced investigators reduce protocol deviations and improve data integrity throughout a study. Together, these advantages make the combined Headlands-CTR network a stronger partner for sponsors seeking speed, quality, and geographic reach. About Headlands Research. Headlands Research is a leading clinical trial site organization with a mission to improve lives by advancing innovative medical therapies. The company operates a growing network of wholly owned clinical research sites across North America and Europe. Headlands provides sponsors and CROs with access to experienced investigators, diverse patient populations, and centralized operational support across therapeutic areas including CNS, vaccines, metabolic diseases, obesity, respiratory disease, cardiometabolic disorders, and more.